← Eichor
Condition: Impaired Hepatic Function Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Impaired Hepatic Function

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pharmacokinetics of VC005 Tablets in Subjects With Hepatic Impairment and Normal Hepatic Function
Phase 1 · 1 location(s) · Jiangsu vcare pharmaceutical technology co., LTD · NCT07551557A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment
Phase 1 · 2 location(s) · Edgewise Therapeutics, Inc. · NCT07324616Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
Phase 1 · 3 location(s) · SpringWorks Therapeutics, Inc., a healthcare company of Merc · NCT06997276A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement
Phase 1 · 1 location(s) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · NCT06985615A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function
Phase 1 · 3 location(s) · Pfizer · NCT07269301A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants
Phase 1 · 3 location(s) · Bristol-Myers Squibb · NCT07248839Resistance Training to Individuals for Cognitive Impairment With Dementia
NA · 1 location(s) · University of Beira Interior · NCT06185010A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Modera
Phase 1 · 3 location(s) · Eli Lilly and Company · NCT07165002Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants
Phase 1 · 3 location(s) · Institut de Recherches Internationales Servier (I.R.I.S.) · NCT07250633Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepati
Phase 1 · 2 location(s) · Atea Pharmaceuticals, Inc. · NCT06911320A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healt
Phase 1 · 3 location(s) · Eli Lilly and Company · NCT07401862To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage
Phase 1 · 1 location(s) · Ganzhou Hemay Pharmaceutical Co., Ltd · NCT06376474A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function
Phase 1 · 3 location(s) · Pfizer · NCT07519135Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Sub
Phase 1 · 1 location(s) · Aligos Therapeutics · NCT07342868A Phase I Clinical Trial to Evaluate the Pharmacokinetic and Safety of Ammoxetine Hydrochloride Enteric-Coated Tablets i
Phase 1 · 1 location(s) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · NCT07694843A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Imp
Phase 1 · 2 location(s) · AstraZeneca · NCT07343960A Pharmacokinetic Study of D-2570 in Participants With Hepatic Impairment and Normal Hepatic Function
Phase 1 · 1 location(s) · InventisBio Co., Ltd · NCT07715149A Study of RAY1225 in Participants With Impaired Liver Function
Phase 1 · 1 location(s) · Guangdong Raynovent Biotech Co., Ltd · NCT06577415Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment
Phase 1 · 3 location(s) · Daiichi Sankyo · NCT06740799Perioperative Analgesia With Erector Spinae Plane Block in Liver Transplant Recipients
NA · 1 location(s) · Bogomolets National Medical University · NCT06857331A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function
Phase 1 · 4 location(s) · Pfizer · NCT07231991Pharmacokinetics of Petrelintide in Participants With Impaired Hepatic Function
Phase 1 · 3 location(s) · Zealand Pharma · NCT07682818Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological
Phase 1 · 4 location(s) · Acrotech Biopharma Inc. · NCT07036133Investigation of Pharmacokinetics,Safety,and Pharmacodynamics of HSK39297 in Subjects With Hepatic Impairment
Phase 1 · 1 location(s) · Haisco Pharmaceutical Group Co., Ltd. · NCT07152288
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.